Edition:
United States

Profile: Vernalis PLC (VER.L)

VER.L on London Stock Exchange

25.00GBp
24 Mar 2017
Change (% chg)

0.12 (+0.50%)
Prev Close
24.88
Open
25.00
Day's High
25.00
Day's Low
24.75
Volume
93,904
Avg. Vol
359,309
52-wk High
53.75
52-wk Low
23.00

Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders. The Company markets three products, including Tuzistra XR in the United States prescription cough cold market; Moxatag, which is a once daily amoxicillin approved in the United States for tonsillitis and pharyngitis, and frovatriptan, which is an acute treatment for migraine. The Company also has four over prescription cough cold products under development and a pipeline of new chemical entity (NCE) development programs and research collaborations.

Company Address

Vernalis PLC

100 Berkshire Place, Wharfedale
WOKINGHAM     RG41 5RD
P: +44118.9380000
F: +44118.9380001

Company Web Links